Waverly Advisors LLC Decreases Stake in Thermo Fisher Scientific Inc. $TMO

Waverly Advisors LLC lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.5% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 30,634 shares of the medical research company’s stock after selling 5,199 shares during the quarter. Waverly Advisors LLC’s holdings in Thermo Fisher Scientific were worth $15,359,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in TMO. Bank OZK purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $1,096,000. Ausdal Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $456,000. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $7,505,000. BlackRock Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth approximately $15,501,867,000. Finally, German American Bancorp Inc. bought a new position in Thermo Fisher Scientific in the second quarter valued at $4,920,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.7%

NYSE:TMO opened at $603.43 on Wednesday. The company has a 50 day simple moving average of $575.12 and a two-hundred day simple moving average of $516.59. The company has a market cap of $223.12 billion, a PE ratio of 32.46, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the firm earned $4.28 earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Piper Sandler lifted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. CLSA started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price target for the company. Finally, Royal Bank Of Canada raised their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $624.64.

Insider Activity

In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.